Loading...
•
Mar 31, 2022
Conmed Q1 2022 Earnings Report
CONMED's first quarter results for 2022 were announced, featuring revenue growth and increased earnings per share.
Key Takeaways
CONMED Corporation reported a 4.1% year-over-year increase in sales, reaching $242.3 million in Q1 2022. Diluted net earnings per share (GAAP) increased by 51.6% to $0.47, and adjusted diluted net earnings per share increased by 11.1% to $0.70.
Sales increased by 4.1% year over year, totaling $242.3 million.
Domestic revenue increased by 5.9% year over year.
Diluted net earnings per share (GAAP) increased by 51.6% to $0.47.
Adjusted diluted net earnings per share increased by 11.1% to $0.70.
Revenue by Segment
Forward Guidance
The Company is raising its revenue guidance for the full year 2022 and now expects revenue between $1.105 billion and $1.150 billion. The Company now expects full-year 2022 adjusted diluted net earnings per share in the range of $3.50 to $3.65.
Positive Outlook
- Revenue guidance raised for full year 2022 to $1.105 billion - $1.150 billion.
- Foreign exchange expected to be immaterial to full-year 2022 revenue growth.
- Includes approximately $20 million in revenue in the back half of 2022 related to the acquisition of In2Bones Global, Inc.
- Acquisition is subject to customary closing conditions, including receipt of U.S. regulatory approval.
- Full-year 2022 adjusted diluted net earnings per share in the range of $3.50 to $3.65.
Challenges Ahead
- New guidance range includes the impact of increased inflation.
- Dilution of $0.05 to $0.10 related to the acquisition.
- Facing larger than anticipated inflationary pressures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...